Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Live Attenuated Vaccines Market Poised To Hit $41.1 Billion By 2030 With A 9.6% CAGR
The live attenuated vaccines market has experienced robust growth in recent years. It is forecast to grow from $25.95 billion in 2025 to $28.52 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 9.9%. The market’s past expansion is attributable to the global infectious disease burden, government immunization initiatives, childhood vaccination policies, hospital-based vaccine delivery, and WHO vaccination programs.
The live attenuated vaccines market is projected to experience robust expansion over the coming years. Its valuation is anticipated to reach $41.11 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.6%. This anticipated rise during the projected timeframe stems from factors such as the increasing need for booster vaccinations, the emergence of infectious disease threats, the broadening of cold chain infrastructure, augmented global health financing, and advancements in next-generation vaccine technologies. Key developments expected during this outlook period encompass the expansion of national immunization initiatives, a rising need for childhood vaccinations, improvements in vaccine stability and storage methods, a heightened emphasis on readiness for pandemics, and the creation of multivalent vaccines.
Get A Free Sample Report With In-Depth Market Insights:
Live Attenuated Vaccines Market Growth Drivers: What’s Behind The Acceleration?
The expanding occurrence of infectious diseases is anticipated to boost the live attenuated vaccines market in the future. These diseases are conditions resulting from detrimental microorganisms such as bacteria, viruses, fungi, or parasites, capable of transmission directly or indirectly among individuals, animals, or environments. The surge in international travel intensifies the dissemination of infectious diseases, enabling pathogens to traverse borders more rapidly than control measures. Live attenuated vaccines play a crucial role in preventing infectious diseases by inducing a robust immune response using attenuated pathogens, thereby guaranteeing lasting immunity and curbing disease transmission. For example, in March 2025, the World Health Organization, an intergovernmental body located in Switzerland, reported that in 2023, approximately 10.8 million individuals globally contracted TB, comprising 6.0 million men, 3.6 million women, and 1.3 million children. Consequently, the rising incidence of infectious diseases is fueling the expansion of the live attenuated vaccines market.
Live Attenuated Vaccines Market Segmentation: How Does The Market Break Down By Category?
The live attenuated vaccines market covered in this report is segmented –
1) By Vaccine Type: Monovalent, Multivalent
2) By Route Of Administration: Intramuscular, Subcutaneous, Oral Attenuated, Intranasal Attenuated
3) By Indication: Influenza, Measles, Mumps and Rubella (MMR), Polio, Chickenpox, Shingles, Rotavirus, Other Indications
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
5) By End-User: Hospitals, Clinics, Diagnostic Centers, Research Institute, Other End-Users
Subsegments:
1) By Monovalent: Single-Dose Vaccines, Multiple-Dose Vaccines
2) By Multivalent: Bivalent Vaccines, Trivalent Vaccines, Quadrivalent Vaccines, Other Multivalent Vaccines
Live Attenuated Vaccines Market Trends: What’s Defining The Industry’s Next Phase?
Leading companies in the live attenuated vaccines market are concentrating on developing advanced products such as single-dose vaccines to improve immunization efficiency and enhance patient compliance. Single-dose vaccines deliver lasting immunity with just one shot, removing the necessity for multiple doses. This simplifies the vaccination process for both patients and healthcare providers, boosting convenience and accessibility. For instance, in November 2023, Valneva SE, a France-based biotech company that develops vaccines for infectious diseases, revealed the launch of IXCHIQ, which gained approval from the U.S. Food and Drug Administration (FDA), a US-based health agency. This vaccine stands as the world’s first live-attenuated chikungunya vaccine designated for adults aged 18 and older. This approval carries significant weight because IXCHIQ is the world’s initial licensed vaccine for chikungunya, addressing a previously unmet medical need for protection against this mosquito-borne viral disease, known for causing severe fever, joint and muscle pain, and various other symptoms.
Live Attenuated Vaccines Market Competitive Overview And Top Companies
Major companies operating in the live attenuated vaccines market are Merck & Co. Inc., Sanofi SA, AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, CSL Limited, GC Biopharma, Serum Institute of India Pvt. Ltd., Bavarian Nordic, Valneva SE, Southern Research, BioFarma, Bharat Biotech International Limited, Meissa Vaccines Inc., BioDiem Ltd., Bio-Med Limited, Naobios, Lakshmi Pharmaceuticals
View The Full Live Attenuated Vaccines Market Report:
Live Attenuated Vaccines Market Geographic Analysis: Where Is Demand Rising Fastest?
North America was the largest region in the live attenuated vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the live attenuated vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model